Melanoma Trial, Recruiting (NCT05446155)

Melanoma Trial, Recruiting NCT05446155 Sponsor: Region Skane Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT05446155 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are receiving routine dermatology (skin specialist) care at Helsingborg, Lund, or Malmö Hospitals and are scheduled for surgical removal of a suspicious pigmented skin spot that doctors are investigating as a possible melanoma (primary part of the trial)
People who are receiving routine surgical or cancer care at Helsingborg, Lund, Malmö, or Kristianstad Hospitals and are scheduled for surgical removal or a needle sampling procedure for melanoma that has spread to other parts of the body (secondary part of the trial)
People who are able to read and sign a written consent form agreeing to take part

Who may not be able to join:

People whose skin spot or growth — whether it is an original skin lesion or one that has spread — is so small that taking an additional small tissue sample for the study could interfere with the accuracy of the standard medical diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kari Nielsen, Ass. Prof., Lund University Cancer Centre

Phone: +46424061000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05446155

Sponsor: Region Skane

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: +46424061000

More information: https://clinicaltrials.gov/study/NCT05446155

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are receiving routine dermatology (skin specialist) care at Helsingborg, Lund, or Malmö Hospitals and are scheduled for surgical removal of a suspicious pigmented skin spot that doctors are investigating as a possible melanoma (primary part of the trial)
People who are receiving routine surgical or cancer care at Helsingborg, Lund, Malmö, or Kristianstad Hospitals and are scheduled for surgical removal or a needle sampling procedure for melanoma that has spread to other parts of the body (secondary part of the trial)
People who are able to read and sign a written consent form agreeing to take part

Who may not be able to join:

People whose skin spot or growth — whether it is an original skin lesion or one that has spread — is so small that taking an additional small tissue sample for the study could interfere with the accuracy of the standard medical diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Region Skane

Registry

ClinicalTrials.gov

Start date

4 November 2013

Est. completion

1 December 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Genomic and transcriptomic differences between cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi.; Interindividual genomic and transcriptomic differences in metastatic melanoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov